微芯生物(688321)
 
 
  日线
顶尖财经网欢迎您!
  K线
 
 最新动态
  投资评级

研究机构 评级日期 最新评级 上次评级
暂无数据
  盈利预测
据微芯生物三季报分析:

  盈利能力明显改善,企业经营效益扭亏为盈

  成长能力有所加强,营利增速步入上升通道

  偿债能力有所加强,偿还流动负债能力很强

  运营能力维持稳定,存货变现能力有所增强

  现金流能力有所加强,公司现金回收质量略差

  财务数据
    截至第三季度实现净利润0.68亿元,每股收益0.26元。

    截至第三季度最新股东权益173193.24万元,未分配利润13682.66万元。

    截至第三季度最新总资产315422.38万元,负债142229.14万元。

利润表
报告期2023-09-302023-06-302023-03-312022-12-31
营业总收入348,588,993.34241,603,895.8106,525,525.73529,939,477.47
营业总成本534,287,482.27384,048,599.6144,662,416.93526,520,422.88
营业利润114,533,476.42160,541,516.13-33,066,257.515,973,634.8
利润总额113,917,851.32160,521,752.07-33,067,28915,156,960.56
净利润68,432,323.32116,038,712.19-35,783,904.5812,816,053.21
其他综合收益1,941,210.12,382,654.95-958,990.666,539,153.72
综合收益总额70,373,533.42118,421,367.14-36,742,895.2419,355,206.93
资产负债表
报告期2023-09-302023-06-302023-03-312022-12-31
流动资产合计1,092,223,550.881,136,672,124.41,253,859,413.431,184,135,081.82
非流动资产合计2,062,000,289.682,024,480,854.621,755,465,103.031,711,664,331.13
资产总计3,154,223,840.563,161,152,979.023,009,324,516.462,895,799,412.95
流动负债合计351,429,393.49369,501,104.12640,366,092.52540,540,942.66
非流动负债合计1,070,862,055.61,011,671,649.71793,464,818.51779,557,609.89
负债合计1,422,291,449.091,381,172,753.831,433,830,911.031,320,098,552.55
归属于母公司股东权益合计1,731,932,391.471,779,980,225.191,454,331,002.161,515,466,737.95
股东权益合计1,731,932,391.471,779,980,225.191,575,493,605.431,575,700,860.4
负债和股东权益合计3,154,223,840.563,161,152,979.023,009,324,516.462,895,799,412.95
现金流量表
报告期2023-09-302023-06-302023-03-312022-12-31
经营活动现金流入小计390,534,387.87249,162,145.72116,014,752.07566,401,990.75
经营活动现金流出小计502,547,542.19370,541,841.75164,597,669.21523,105,725.3
经营活动产生的现金流量净额-112,013,154.32-121,379,696.03-48,582,917.1443,296,265.45
投资活动现金流入小计750,839,196.43498,386,791.08293,077,432.2645,919,625.04
投资活动现金流出小计1,135,517,773.31714,618,586.9301,731,816.271,447,623,336.66
投资活动产生的现金流量净额-384,678,576.88-216,231,795.82-8,654,384.07-801,703,711.62
筹资活动现金流入小计544,264,528.43479,164,528.43188,917,278.431,137,600,665.3
筹资活动现金流出小计205,213,458.73167,352,625.7629,421,738.64276,312,533.43
筹资活动产生的现金流量净额339,051,069.7311,811,902.67159,495,539.79861,288,131.87
汇率变动对现金及现金等价物的影响1,997,965.333,449,712.09-1,053,029.412,230,570.39
现金及现金等价物净增加额-155,642,696.17-22,349,877.09101,205,209.18115,111,256.09
期末现金及现金等价物余额259,625,367.22392,918,186.3516,473,272.57415,268,063.39
  主营收入+营业利润
 
  净利润+每股收益
  股东权益+未分配利润
 
  总资产+负债
  投资要点

    截至第三季度实现净利润0.68亿元,每股收益0.26元。

    截至第三季度最新股东权益173193.24万元,未分配利润13682.66万元。

    截至第三季度最新总资产315422.38万元,负债142229.14万元。

利润表
报告期2023-09-302023-06-302023-03-312022-12-31
营业总收入348,588,993.34241,603,895.8106,525,525.73529,939,477.47
营业总成本534,287,482.27384,048,599.6144,662,416.93526,520,422.88
营业利润114,533,476.42160,541,516.13-33,066,257.515,973,634.8
利润总额113,917,851.32160,521,752.07-33,067,28915,156,960.56
净利润68,432,323.32116,038,712.19-35,783,904.5812,816,053.21
其他综合收益1,941,210.12,382,654.95-958,990.666,539,153.72
综合收益总额70,373,533.42118,421,367.14-36,742,895.2419,355,206.93
资产负债表
报告期2023-09-302023-06-302023-03-312022-12-31
流动资产合计1,092,223,550.881,136,672,124.41,253,859,413.431,184,135,081.82
非流动资产合计2,062,000,289.682,024,480,854.621,755,465,103.031,711,664,331.13
资产总计3,154,223,840.563,161,152,979.023,009,324,516.462,895,799,412.95
流动负债合计351,429,393.49369,501,104.12640,366,092.52540,540,942.66
非流动负债合计1,070,862,055.61,011,671,649.71793,464,818.51779,557,609.89
负债合计1,422,291,449.091,381,172,753.831,433,830,911.031,320,098,552.55
归属于母公司股东权益合计1,731,932,391.471,779,980,225.191,454,331,002.161,515,466,737.95
股东权益合计1,731,932,391.471,779,980,225.191,575,493,605.431,575,700,860.4
负债和股东权益合计3,154,223,840.563,161,152,979.023,009,324,516.462,895,799,412.95
现金流量表
报告期2023-09-302023-06-302023-03-312022-12-31
经营活动现金流入小计390,534,387.87249,162,145.72116,014,752.07566,401,990.75
经营活动现金流出小计502,547,542.19370,541,841.75164,597,669.21523,105,725.3
经营活动产生的现金流量净额-112,013,154.32-121,379,696.03-48,582,917.1443,296,265.45
投资活动现金流入小计750,839,196.43498,386,791.08293,077,432.2645,919,625.04
投资活动现金流出小计1,135,517,773.31714,618,586.9301,731,816.271,447,623,336.66
投资活动产生的现金流量净额-384,678,576.88-216,231,795.82-8,654,384.07-801,703,711.62
筹资活动现金流入小计544,264,528.43479,164,528.43188,917,278.431,137,600,665.3
筹资活动现金流出小计205,213,458.73167,352,625.7629,421,738.64276,312,533.43
筹资活动产生的现金流量净额339,051,069.7311,811,902.67159,495,539.79861,288,131.87
汇率变动对现金及现金等价物的影响1,997,965.333,449,712.09-1,053,029.412,230,570.39
现金及现金等价物净增加额-155,642,696.17-22,349,877.09101,205,209.18115,111,256.09
期末现金及现金等价物余额259,625,367.22392,918,186.3516,473,272.57415,268,063.39
  十大流通股东
十大流通股东 报告期:2023-09-30
股东名称 持股数量(万股) 占总股本比例(%) 上期持股变化(万股)
博奥生物集团有限公司3470.528.440.00
深圳市海粤门生物科技开发有限公司2293.605.580.00
LU XIANPING2223.965.412223.96
深圳海德睿博投资有限公司1981.744.820.00
深圳市海德康成投资合伙企业(有限合伙)1515.533.68-13.00
Vertex Technology Fund (III) Ltd1317.473.200.00
南昌海德睿远企业管理合伙企业(有限合伙)1175.382.860.00
深圳市海德睿达企业管理合伙企业(有限合伙)1175.382.860.00
深圳市海德鑫成企业管理合伙企业(有限合伙)941.652.290.00
天府清源控股有限公司821.442.000.00
  主力控盘
  公司简介
微芯生物 所属地域: 广东省 涉及概念: 年报预增,沪股通,创新药,生物医药,融资融券
主营业务: 药物技术开发、相关成果商业应用;新药研究、开发、技术转让及其它有关的服务;新治疗技术研究、开发、技术转让及其它有关的服务;对外专利、技术的许可授权。药品的生产;保健食品生产经营(以上不含限制类项目,涉及行政许可和专项规定管理,需取得相关资质方可经营)。
上市日期: 2019-08-12 每股净资产: 3.91元 每股收益: 0.26元 净利润: 1.08亿元 净利润增长率: 356.05%
营业收入: 3.49亿元 每股现金流: -0.27元 每股公积金: 2.77元 每股未分配利润: 0.33元 总股本: 4.11亿 流通股: 4.11亿
以上信息为合作方、加盟公司及会员收集,本站不拥有版权,版权归原作者所有,所载文章、数据仅供参考,据此操作,风险自负。

中 华 顶 尖 财 经 -- 中 华 顶 尖 网 络 信 息 服 务 中 心